[Neuroimmunopathological mechanisms of preclinical epileptogenesis and their correction by cycloferon]

Area of Science:

• Neuroscience
• Immunology
• Pharmacology

Background:

• Preclinical epilepsy involves complex immunological processes.
• Understanding immune system disturbances is crucial for early epilepsy management.

Purpose of the Study:

• To investigate the immunologic peculiarities in preclinical epileptogenesis.
• To evaluate the immunocorrecting potential of Cycloferon in early epilepsy.

Main Methods:

• Clinical, electroencephalogram (EEG), and biochemical examinations were performed on 62 patients.
• Epileptogenesis expression was categorized as regressed, compensated, increasing, or decompensated.

Main Results:

• Preclinical epilepsy stages exhibit altered immunological brain reactivity.
• Decreased compensatory epileptogenesis correlates with neuroimmune interaction disintegration and mixed-type immunodeficiency.
• Immune disturbances were noted to be more severe with decreased compensation.

Conclusions:

• Cycloferon demonstrates potential as a multilevel immuno-correcting agent for initial epilepsy stages.
• Targeting immune dysregulation with Cycloferon may be beneficial in managing preclinical epileptogenesis.